Published in:
Open Access
01-12-2022 | Tyrosine Kinase Inhibitors | Case report
Regorafenib-induced renal-limited thrombotic microangiopathy: a case report and review of literatures
Authors:
Qinghua Yin, Na Guo, Xueli Zhou, Huan Xu, Song Lei, Ping Fu, Hui Zhong
Published in:
BMC Nephrology
|
Issue 1/2022
Login to get access
Abstract
Background
Regorafenib belongs to a sub-group of small-molecule multi-targeted tyrosine kinase inhibitors(TKIs). In various studies with respect to the side-effect of regorafenib, drug-associated proteinuria standardly qualified to be defined as nephrotic syndrome was rarely reported as well as the relation of regorafenib with the occurrence and development of thrombotic microangiopathy (TMA).
Case presentation
In this case report and literature review, we presented a 62-year-old patient receiving regorafenib for metastatic colon cancer, manifesting abundant proteinuria, in which TMA was also diagnosed through renal biopsy. As far as we were concerned, this was the first reported in terms of regorafenib-induced TMA confirmed by renal biopsy.
Conclusion
This case indicates that regorafenib, a kind of TKIs may result in TMA, which is a rare but life-threatening complication of cancer treatment drug. Insights from this case might help physicians diagnose rare forms of TMA and adjust treatment for patients in a timely manner.